BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript

Philip Serlin: Yes. Thank you, operator. To summarize, we entered 2023 with significant momentum. We are preparing for the potential U.S. approval of our first therapy in stem cell mobilization and have successfully completed the formation of our U.S. commercial leadership team. We are also making notable progress with our PDAC program and anticipate important data from a first-line investigator initiated later this year as well as the initiation of our GenFleet collaboration study. We have also taken additional life cycle management steps by entering into a collaboration to execute a clinical trial with Motixafortide as a mobilization agent in gene therapies. I am extremely pleased with our progress during the fourth quarter and the full year and I’m excited about what we are on the cusp of achieving this year.

Thank you all very much for your continued interest in BioLineRx and we look forward to providing our next comprehensive update in May. Be safe and have a great day.

Operator: Thank you. This concludes the BioLineRx 2022 financial results conference call. Thank you for your participation. You may go ahead and disconnect.